--- title: "Estrella Immunopharma (ESLA) news: going concern" url: "https://aibio.space/companies/estrella-immunopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ESLA going concern and Nasdaq notice news: Estrella Immunopharma gets Nasdaq deficiency notice on $35,000,000 market value requirement." --- ESLA Estrella Immunopharma, Inc. NASDAQ · United States # Estrella Immunopharma (ESLA) news ESLA going concern and Nasdaq notice news Listings · 2026-08-21 ## [Estrella Immunopharma gets Nasdaq minimum bid price notice, has until February 16, 2027 to comply](https://aibio.space/news/estrella-immunopharma-gets-nasdaq-minimum-bid-price-notice-has-until/) Nasdaq notified Estrella on August 17, 2026 that its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance. Its year-end 2025 cash was $1.4 million. ## Latest Estrella Immunopharma news 1. 2025-09-29 Listings [Estrella Immunopharma regains Nasdaq compliance on bid price and market value rules](https://aibio.space/news/estrella-immunopharma-regains-nasdaq-compliance-bid-price-market-value/) Nasdaq sent two letters on September 23, 2025 closing both matters. The company had been notified of the deficiencies in April and August. 2. 2025-08-07 Listings [Estrella Immunopharma gets Nasdaq deficiency notice on $35,000,000 market value requirement](https://aibio.space/news/estrella-immunopharma-gets-nasdaq-deficiency-notice-35-000-000-market/) Nasdaq told Estrella on August 1, 2025 that its market value of listed securities fell below the $35,000,000 minimum. It has until January 28, 2026 to regain compliance, and its annual report for the year ended June 30, 2024 carried a going-concern warning. ## Estrella Immunopharma at a glance - **Ticker**: ESLA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $100,000 ### Related companies - [Septerna](https://aibio.space/companies/septerna/) NASDAQ: SEPN - [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO - [Cel-Sci](https://aibio.space/companies/cel-sci/) AMEX: CVM - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) AMEX: MAIA - [Kailera Therapeutics](https://aibio.space/companies/kailera-therapeutics/) NASDAQ: KLRA - [Seres Therapeutics](https://aibio.space/companies/seres-therapeutics/) NASDAQ: MCRB - [GlobeStar Therapeutics](https://aibio.space/companies/globestar-therapeutics/) OTC: GSTC - [Recursion Pharmaceuticals](https://aibio.space/companies/recursion-pharmaceuticals/) NASDAQ: RXRX ### Also on NASDAQ - [CARLSMED, INC.](https://aibio.space/companies/carlsmed/) CARL - [Glucotrack](https://aibio.space/companies/glucotrack/) GCTK - [Tonix Pharmaceuticals Holding](https://aibio.space/companies/tonix-pharmaceuticals/) TNXP - [MiniMed Group](https://aibio.space/companies/minimed/) MMED - [Krystal Biotech](https://aibio.space/companies/krystal-biotech/) KRYS - [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) SBFM ## Estrella Immunopharma annual financials | Line | FY2025 | FY ended Jun 30, 2024 | |---|---|---| | Research and development | [$10.2 million](https://www.sec.gov/Archives/edgar/data/1844417/000121390026029357/) | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1844417/000121390024082374/) | | Net income (loss) | [-$13.1 million](https://www.sec.gov/Archives/edgar/data/1844417/000121390026029357/) | [-$7.3 million](https://www.sec.gov/Archives/edgar/data/1844417/000121390024082374/) | | Cash from operations | [-$1.8 million](https://www.sec.gov/Archives/edgar/data/1844417/000121390026029357/) | [-$16.1 million](https://www.sec.gov/Archives/edgar/data/1844417/000121390024082374/) | | Cash and equivalents | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1844417/000121390026029357/) | [$4.2 million](https://www.sec.gov/Archives/edgar/data/1844417/000121390024098450/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $100,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Estrella Immunopharma Has Estrella Immunopharma issued a going-concern warning? Our latest story on this, dated Aug 7, 2025: "Estrella Immunopharma gets Nasdaq deficiency notice on $35,000,000 market value requirement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/estrella-immunopharma-gets-nasdaq-deficiency-notice-35-000-000-market/). Has Estrella Immunopharma received a Nasdaq deficiency notice? Our latest story on this, dated Aug 7, 2025: "Estrella Immunopharma gets Nasdaq deficiency notice on $35,000,000 market value requirement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/estrella-immunopharma-gets-nasdaq-deficiency-notice-35-000-000-market/). What is the ticker symbol of Estrella Immunopharma? Estrella Immunopharma, Inc. trades under the ticker ESLA on NASDAQ. Where is Estrella Immunopharma listed? Estrella Immunopharma, Inc. is listed on NASDAQ. What is the SEC CIK of Estrella Immunopharma? The SEC Central Index Key (CIK) for Estrella Immunopharma, Inc. is 1844417. Its filings are on SEC EDGAR. How many shares does Estrella Immunopharma have outstanding? 43,497,864 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Estrella Immunopharma listed under? Our directory records Estrella Immunopharma, Inc. under United States. What does Estrella Immunopharma do? Our directory classifies Estrella Immunopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Estrella Immunopharma? The ISIN recorded for Estrella Immunopharma, Inc. is US2975841048. Does aibio.space cover Estrella Immunopharma? aibio.space lists Estrella Immunopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is Estrella Immunopharma profitable? Estrella Immunopharma, Inc. reported a net loss of $13.1 million for the fiscal year ended Dec 31, 2025, and used $1.8 million of cash in operations, per its annual report to the SEC. How much does Estrella Immunopharma spend on research and development? $10.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Estrella Immunopharma have? $100,000 in cash at Jun 30, 2026, per its 10-Q. What is the latest Estrella Immunopharma (ESLA) stock news? Our latest story on Estrella Immunopharma, dated Aug 21, 2026: "Estrella Immunopharma gets Nasdaq minimum bid price notice, has until February 16, 2027 to comply". Nasdaq notified Estrella on August 17, 2026 that its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance. Its year-end 2025 cash was $1.4 million. [Source](https://aibio.space/news/estrella-immunopharma-gets-nasdaq-minimum-bid-price-notice-has-until/). How long will Estrella Immunopharma's cash last? From our story of Aug 21, 2026: The 10-K states that recurring losses and the need for more financing raise substantial doubt about the company's ability to continue as a going concern, and that it will need substantial additional funding. [Source](https://aibio.space/news/estrella-immunopharma-gets-nasdaq-minimum-bid-price-notice-has-until/). ## Investor discussion: Estrella Immunopharma Members talk about Estrella Immunopharma (ESLA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Estrella Immunopharma, newest first. Each line links the filing it comes from. 1. 2026-09-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390026098123/ea030490301-8k_estrella.htm) 2. 2026-08-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390026092657/ea0303066-8k_estrella.htm) 3. 2026-05-18 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390026058062/ea0291212-nt10q_estrella.htm) 4. 2026-03-18 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390026029357/ea0276230-10k_estrella.htm) 5. 2026-01-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390026003998/ea027282201-8k_estrellaimmu.htm) 6. 2026-01-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390026001686/ea0271992-424b5_estrella.htm) 7. 2025-09-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390025093197/ea0259355-8k_estrella.htm) 8. 2025-08-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390025072746/ea0252082-8k_estrella.htm) 9. 2025-05-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390025039261/ea0240454-8k_estrella.htm) 10. 2024-12-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390024109285/ea0224902-8k_estella.htm) 11. 2024-11-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1844417/000121390024102134/ea0222513-8k_estrella.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ESLA on TradingView](https://www.tradingview.com/symbols/NASDAQ-ESLA/). ## SEC filings and registration - **SEC name**: Estrella Immunopharma, Inc. - **CIK**: 1844417 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ESLA (Nasdaq), ESLAW (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 5858 HORTON STREET, SUITE 370, EMERYVILLE, CA, 94608 - **Phone**: (510) 318-9098 - **Shares outstanding**: 43,497,864 as of 2026-08-11 (10-Q filed 2026-08-13) - **Former names**: TradeUP Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1844417/000121390026098123/ea030490301-8k_estrella.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1844417/000121390026092657/ea0303066-8k_estrella.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1844417/000121390026089215/ea0300821-10q_estrella.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1844417/000121390026073847/ea029661701-8k_estrella.htm) filed 2026-06-30 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1844417/000114036126023012/ny20074256x1_def14a.htm) filed 2026-05-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1844417/000121390026058063/ea0288520-10q_estrella.htm) filed 2026-05-18 - [10-K](https://www.sec.gov/Archives/edgar/data/1844417/000121390026029357/ea0276230-10k_estrella.htm) filed 2026-03-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1844417/000121390026003998/ea027282201-8k_estrellaimmu.htm) filed 2026-01-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001844417), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Estrella Immunopharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ESLA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Estrella Immunopharma, Inc. - **Ticker**: ESLA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US2975841048 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ESLA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/estrella-immunopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Estrella Immunopharma (ESLA) news: going concern", 2026-10-31, https://aibio.space/companies/estrella-immunopharma/